LUMICKS provides single-molecule analysis technologies for cancer research and immunotherapy.
Lumicks has raised €97M across 2 funding rounds from 1 investor, most recently a Debt round in Oct 2024. Based in Amsterdam, Netherlands; founded 2014; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2024-10-10 | Debt | €20M | European Investment Bank (EIB) | View deal → |
| 2021-04-21 | Other | €77M | — | View deal → |
